Cullen/Frost Bankers, Inc. Altimmune, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 10,000 shares of ALT stock, worth $66,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$66,100% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ALT
# of Institutions
190Shares Held
39MCall Options Held
926KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$35.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.43MShares$29.3 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$25.6 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$22.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.2 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $324M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...